{"title": "PDF", "author": "PDF", "url": "https://ripetomato2uk.files.wordpress.com/2021/04/bentov.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "cleaned_text": "Ovarian foll icular fu nction i s not al tere d by SARS-Cov-2 infection o r Hananel E. G. Holzer, M.D. 2,5 Dana Wolf, M. olog Hadassa sity Med ical Center, Jerusale m 2. Depart ment of Ob stetrics a nd G yn ec ology, Hadas sah Mount Scopu s-H ebr ew Unive rsity medical cent er, Je rusale m , Israel 3. Clinical Virology Unit, Hadassah H eb rew U nive rsity u salem 5. Faculty of M edicine, He bre w Univ er s ity of Jerusale m, I srael. \u00a5 Corres pondin g author \u00a7 COVID 19 disease and BNT mRNA tio n nor vaccina tion appear to negative l y effec t fo llicu lar function. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted April 13, 2021. ; https://doi.org/10.1101/2021.04.09.21255195doi: medRxiv preprint NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.Ovarian foll icular fu nction i s not al tere d by SARS-Cov-2 infection o r BNT162b2 mRNA Covid-19 vaccination. Ab stract: Importance: Th is is th e fi rs t s tudy to exa mine th e imp ac t of SA RS-C ov- 2 infe ct ion and COVID-19 va cc ina ti on on o va rian fu ncti on. Obj ective : To ch te rize ant i-C O VID-19 ant ib odi es in foll ic ular fluid and c omp ar e ova ri an foll icl e func ti on in w om en f ollow ing confi rm ed S ARS- CoV-2 infec ti COVID-19 vac c inat n on-infe ct ed, un va cc inat ed con tr ols. Design Th is is a c oho rt st udy c ondu ct ed b et we en F ebr ua ry 1 and Ma rc h 10, 2 021. Setting: A single uni ve rsi ty ho spi tal -bas ed IVF cl ini c. Participants: Cons e cut iv e s ampl e o f femal e p ati ent s unde rgo ing oo cy te re tr iev al. Interventions: C onsen ting p at ient s we re recruited and assigned to one of three study groups: re co ver ing fr o m c onfi rm ed COVID 1 9 (n=9) ; va cc ed inat ed con (n=14) . Se ru m and folli cula r flu id s ampl es we re ta ken and analyzed fo r anti- COVID IgG as well as e str og en, prog est er one and HSP G2 con cent ra ti on, a s well as the numb er and m at uri ty of asp ira ted o oc yt es and pr ev iou s est rog en and p rog est er one mea sur em ent s. Main outcom e m eas ure s : Foll ic ula r func ti on, includ ing s te ro idog ene si s, the an d o oc yt e q uali ty b io ma rke rs. Resu lts: Bo th na tur al and v ac cin e e lici ted ant i-C OVID IgG anti b odi es w ere de te ct ed in th e follic ular fluid in le vel s pr opo rt ion a l to th e I gG ser um c onc entr at ion. N o diff eren ce s w er e dete ct ed in an y of th e sur rog at e ova rian f olli cle qu ali ty rep or ting p ar am ete rs . Conclusions and r el ev ance: Bo th SARS-C OV-2 infe ct i on and va cc ina ti on w ith th e BNT1 62b2 m RN A va cc ine med ia te I gG i mmun it y t hat c ro ss es int o t he f olli cular fluid . No detr im ent al effe ct on folli cula r fun c ti on w as d et ec ted . Trial Re gistration: Cin ic alT ri als.g o v r egi str y nu mb er N CT0482 2012 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted April 13, 2021. ; https://doi.org/10.1101/2021.04.09.21255195doi: medRxiv preprint Introduction: Since e me rging in t he l as t m onth s o f 2019, ov er 127,000 ,000 indiv idu als ha ve c ontr a cte d confi rm ed S ARS-C oV-2 infec ti on, an d th e do cu men ted d ea th toll fro m C OVID-19 h ad rea ch ed 2, 788,639 indi vid uals glo b ally by the end of Ma rch , 2021 1 . J er usale m, th e s et ting of th e p res ent stu dy, ha s pr es ented one of t he high es t incid enc e rat es of COVID-19 in Isr ael 2 . Na ti onwid e anti- COVID-19 va c cina t ion beg an in Is ra el in D ec em be r 20 20, us ing t he Pfize r - Bio Nt e ch v a cc ine (B NT162 b2 mR N A). By th e end of M ar ch 202 1, 5 ,216 ,801 and 4,700 ,957 indiv idual s r ec ei ved th e fi rs t and se cond d os es of the v ac cin e, rep res en ting 56 .1% and 50.55% of Is ra el's p opula ti on, re spe ct ivel y. V ac cin at ion f or rep rod uc ti v e ag e indiv idual s beg an in Janu ar y 2021 ; b y the end o f Ma rc h 2021 , 72.3 % and 61 .3% of 20-29 ye ar old s, 77.1% and 67 .8 % of 30-39 ye ar old s, and 82% and 74.5 % of 40-49 ye a r old s h ad r e ce ived the f ir st and s ec ond d os es of the va cc ine, r espe ct iv ely, th e h igh est pr op ort i ons in th e world2 . Bot h t he rap idly spre ading di sea se and th e v a cc inat ion c amp aign we re ass oc ia ted wi th con ce rns r ega rding po tent ial det ri ment al eff ec on fut ur e fe rt ilit y3-5 . The re is st ill a la ck of real- wo rld da ta t o a ss ist cl ini ci ans i n co unsel ing th ei r IVF pa ti ents re ga rding the po ssi ble impa ct of re c ent re co ve ry f ro m COV ID infe ct ion o r v ac cin at ion aga inst i t, on t he p ot ent ial for suc ce ss of ass is ted rep rod uc ti ve tr ea tm ents . W hil e i t h as be en s ugg est ed tha t COVID-19 migh t impa c t fe rt ilit y, n o stud ies , to the b es t of ou r kn owle dge, ha ve pr ov en a d ir ec t gonadal effe ct of ei th er the di se ase or th e v ac cin e 4-8 . We ai med t o d et er mine th e impa c t of c onfi rm ed C OVID-19 d is eas e and /or i mmun izat ion on hu man f olli cula r func ti on, by c o mpar ing foll ic ular st er oi dog enes resp onse t o the LH/h CG tri gge r, and o o cyt e qual it y bi om ark er (HSPG 2), in th e a spir at e d folli cula r fluid of pati ents unde rgo ing ovu m pi ck-up. Method s: The st udy was app ro ved by th e H ad ass ah Med ic al Cent er I RB (Pe rm it 0 053-21-HM O ). Th e study w as reg is ter ed at th e clini cal t rial r egis tr y and as sign ed t he reg is t rat ion num be r . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted April 13, 2021. ; https://doi.org/10.1101/2021.04.09.21255195doi: medRxiv preprint NC 0053-21 -HMO ). C onse cut iv e p ati ent s unde r going OPU f or ei the r IVF, I CSI , or o oc yte c ry opr es erv at io n wer e appr oa ched t o pa rt ic ipa te in the s tudy on the day of ovu m pi ckup . Eligi bil it y cr ite ria w ere ag e olde r t han 18 y ear s and willingn ess t o part ic ipa te and pr ov ide info rm ed c onsen t. Pa tien ts yo unger th an 18 o r old er th an 44 yea rs, a s w ell a s pa ti ents w ith po or ova ri an r esp onse (l ess th an 3 ma tu re f olli cles ) wer e exclude d. Afte r pr ov iding info rm ed cons ent , t he pa ti ents w er e q ues ti oned a bou t t hei r confi rm ed pa st SARS-C ov-2 infe ct ion / va cc inat tus . F or re c ov ering pat ien ts, th e date of th e r ec o ver y (nega ti ve n as opha ryng eal COVID P CR te st ) w as re c ord ed. V ac cina ted p ati ents w er e a sked ab out th e da te of th e fi rs t and se c ond va cc ine s. Non e of th e re co ve ring p ati ents w er e vac c inat ed w it h an ti-C OVID va cc ine . Th e clini c' s s tr ic t p oli cy is t o s cr ee n all pa tien ts using a nasoph ar yngeal sw ab fo r C OVID-19 a w eek pr io r t o th e pr oc edu re, ex ce pt th os e p ati ent s who we re les s than 3 m onth s foll o wing r e co ve ry f ro m SA RS-C ov-2 inf ec ti on, and th os e mo re th an 2 w eek s afte r the se c ond COVID-19 v a cc ine. As a re sult , t og e the r w ith th e negat iv e an ti-C OVID se rum ant ib od y t est , w e c ould s afely pr esu me th at all cont rol pat ien ts in th is stud y wer e inde ed C OVID-19 nega tiv e. Dur ing th e oo c yte r et ri ev al th e fi rs t foll icl e/s wer e aspi ra ted int o an e mpt y tu be . If th e s ampl e w as c onta min at ed w it h bl ood ano th er clean sa mple wa s tak en, unt il a t ot a l volu me of 5 ml of a cle an s ample w as ach ie ved . A 5 ml blo od s ampl e w as als o tak en dur ing the pr oc edu re. F ollow ing t he is ola t ion of t he o oc yt e, the FF was c ent rifug ed a t 150 0g an d th e bl oo d s ampl e a t 3000g fo r 7 minut es . T he supern at ant fr ac ti on of t he f olli cula r fluid and the se ru m fr ac ti on of th e blo od sa mple we re ea ch aliq uo ted and l ate r snap fr oze n and s to red at -80 C\u00b0 unt il an alys is. Data incl uding the pa ti ent age, IVF i ndica ti on, antr al f olli cle co unt (AF C ), ser um es tr adi ol and pr oges te ron e on th e d ay of ovu lati on t rig ger (36 h our s b efo re o oc y te re tr iev al) , t ype of trigg er , t he num ber of o oc yt es, and mat ur e o o cy tes , w er e re co rded . Once th e tar get da te wa s r ea ch ed th e s ample s wer e tha wed and analyze d for th e foll ow ing ass ays . The anal ysi s t he blo od an d FF s ampl es f or all ou tc om e pa ra m ete rs wa s condu ct ed wit h bl inding of the C OVID / Va c cine s tat us of the par ti cip an t. Seru m and folli cula r flu id an ti-C OVI D IgG me asu re ment : . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted April 13, 2021. ; https://doi.org/10.1101/2021.04.09.21255195doi: medRxiv preprint The lev SA RS- Co V-2 spike pr ot ein re cep to r b inding dom ain (R BD) IgG wer e ass ess ed in s eru m and foll icul ar flu id sp ec im ens, us ing t he Ar ch it ec t SA RS-C oV-2 Ig G II Quant a ssa y (A bb ot t Di agno st ic s, Chi cag o, USA) , a c co rding t o th e man ufac tur er' s spec ifi ca ti ons. Ig G le vel s 50 AU/ mL w er e con sid ere d po si ti ve. Ass ess men t of o va ri an folli cle func ti ons: Steroidog enesi s: W e ex am ined the ab ili ty of the Th ec a- g ranulo sa c ells tha t f or m t he wall of th e f olli cles t o pr odu ce st er oi ds, namel y e st rad iol and pr og est er one , by me asu ring th eir con cent ra ti on b o th in th e s er um an d FF. The m eas ure men t w as c onduc ted u sing t he At elli ca I M Si em ens He alth i neer s s yst em (Sie men s H ealt hc ar e G mb H H enkes tr. 127 9105 2 Erlang en G er many ). Est rad iol con cent ra ti on w as me asu red us ing the Enh anc ed Est rad iol Ki t (# 1099 5561) an E LISA bas ed on a cr idin ium-l ab eled she ep i ol ant ib od y wit h a m eas ur ing range of 4 3.31-11,0 10.0 p m ol/L ). F or me asu ring FF es trad i ol, the typ ic al entr at ion of whi ch exc eeds th e me asu ring rang e of the ki t, the sa mple wa s d ilut ed u sing t he At elli ca I M eE2 dilu ent (10995563 ) ac c ord ing t o a pr ot oc ol d es cr ib ed el se whe re 9 . Th e mea sur em ent of s eru m and FF p ro ges te ron e w as condu ct ed u sing the P RG E ki t (1099 5660). Th e k it is bas ed on di re ct c he milu mine sc ent t echn olog y u sing an a cr idin ium-l ab e led m ous e mon ocl onal anti-p rog es ter one ant i bod y w ith a m eas uring int er val of 0 . 67-190.80 n mol/ L. For FF p rog es te ron e m ea sur em ent, the sa mple wa s dil ut ed w ith th e At e llica I M Mult i-diluent (1099 5645) a cc o rding to th e pr ot oc ol 9 . To n or mal ize est rad iol pr odu cti on, we u sed th e r at io of se ru m e st rad io l on t he d ay of th e trigg er pe r r et ri ev ed oo cy te. Th is r a ti o w as f ound in a larg e stud y 10 t o b e an age independ ent pr edi ct o r of IVF tr ea t ment ou tc o me. In tha t stud y an es tr adi ol/o o cy te ra ti o of > 1,000 p m ol/L/ Oo cy te wa s ass o cia ted wi th a r edu ct ion in pr egnanc y a nd clini cal pregnan cy ra te 10. Follicu lar re spons e to th e LH /hC G trigge r a ss es sm ent : . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted April 13, 2021. ; https://doi.org/10.1101/2021.04.09.21255195doi: medRxiv preprint To as ses s the ad equ ac y of r esp onse of th e f olli cle to th e L H/h CG tr igge r we co mpa red th e follow ing pa ra me te rs: 1. Oo cy te yi eld: th e r at io b etw een th e numb er of r et ri ev ed oo cy te s t o the numb er of mat ur e foll icl es me asu red on the da y of th e t rigg er inj ec ti on. Th is ra ti o repr es ents the ab ili ty of the gr anulo sa cell s t o s ec ret e enzym es tha t rel eas e the cu mulus o oc yt e co mplex fr o m t he wall of the folli cle in r esp onse t o the LH surg e, th er eb y all owing its asp ir at ion. An o oc yte y ield of 45 % or l es s w as d efined a s su b-op ti m al 11 . 2. Rat i o of m atu re o oc yt es to t ot al a sp ira ted o oc yt es , r epr esen ting ano the r a spe ct of the ade qu ac y of r esp onse t o t he LH /hCG t rigg er - p ro m oting th e co mpl eti on of t he firs t m ei ot i c di vi si on. 3. Rat i o of th e nu mb er of re tri ev ed oo cyt es t o t he nu m ber of folli cle s t ha t beg an lute inis at ion, o bt ained b y di vid ing t he nu mb er of ret ri ev ed oo cy te s b y t he s eru m con cent ra ti on of pr oge st er one on t he d ay of O PU. Ass es sm ent of oocyte qu ality FF biom ark er s: Con cent ra ti on of Hep ar an Sulpha te Pro te ogly can II in foll ic ular fluid (H SPG2): A pr ote o mi c analys is of ov er 500 F F pr ot ein s id e ntifi ed t he c oncen tr at ion of HSP G2 (Pe arle c an) in FF as the st rong est b io ma rke r to pred ic t oo cy te fer til izat ion and IVF su cc es s 12 . We analyz ed t he c onc entr at ion of H SPG2 in FF u sing th e Hu man HSPG2 Simpl eStep E LISA kit (A bc am , Di sc ov er y Dr iv e, Ca mb r idge Bi om edi cal C ampu s, Ca mb ridg e, CB2 0 AX, UK ). Thi s ELIS A s yst em us es an affinit y t ag la bel ed capt ure ant ib od y and a r epor te r conj uga ted dete ct o r an ti bod y r ead a t 450-600n m. The t est r ange of me asu re ment i s 47 -7, 000 pg/ ml. Diluti on of t he sa mples w ith up t o 1 :50k w as done w ith a p rop er dilu ent. The anal ysi s was condu ct ed ac co rding t o t he manuf a ctu re r's ins tru ct ion s. Stat is ti cal analy si s All anal yse s wer e p erf or med using SPSS 23.0 (SPSS In c., C hi cag o, IL ). C ontinu ou s in ter val s and ra ti os th at we re no t no rm ally d ist ri but ed wer e tr ansfo rm ed t o a l o gari th mi c s cal e f or norm ali ty c or re ct ion. N or mally di st rib ut ed da ta we re c omp ar ed ac ro ss study gr oups b y univa ri at e A N OVA. Ra te s and pr opo rti ons we re c omp ar ed w it h th e Ch i-squ are o r F ish er 's . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted April 13, 2021. ; exac t tes ts as appr opr ia te in ca se of small nu m ber s. C orr ela ti ons we re p res ente d b y s c att er plots and the go odne ss of fi t cal cula ted by R2 . All P valu es we re te st ed a s t wo ta iled and cons ide red si gnifi cant a t <0. 05. Resu lts: Pat ient ar ac te sti cs : Ove rall, 32 p at ient s cons ent ed t o p a rti cip at e in th e stud y, of w hi ch 9 r e port ed va cc ina ti on (Gr oup 1 - Va cc ine) ; 7 t o h av e r ec o ver ed fr o m C OVID (G roup 2 - di se a se) ; and 16 d eni ed bo th and w er e all oc at ed t o th e non- expos ed g roup (G ro up ev er , se rum anal ys is f or the p re sen ce of anti- COVID-19 IgG i dentif ied tw o of t he p at ient s in th e cont r ol gr oup as re co ver ee s fr o m a lik ely asy mpt om ati c S ARS- Co v-2 inf ec ti on and th ere fore w ere r e - alloc at ed to Gr oup 2 . Me an t im e p er iods fr om va c cine o r re co ve ry to r ec rui tm ent and sampl ing w er e a s f ollow s: 93.2 d ay s fro m r e co ve ry to sa mpling (r ange 4 8-169 day s) ; 11 .7 days fro m f irs t va cc ine d os e to sa m pling in the 4 pa ti ents wh o we re re c rui ted aft er co mple ti on of a single v ac cin e d ose (rang e 8-18 day s) and 27 .6 d ays fr o m s ec ond v a cc ine dose t o sa mpling in 5 pa ti ents r ec ru ited aft er c ompl et ing t wo do se s ( ra nge 4-46 d ays ). Pat ien t de m ogr aphi cs ar e d es cr ib e d in T abl e 1 . The m ean age of p art i cipan ts in t he study w as 33 .7 ye ars . A ge wa s foun d to b e no rm ally dist ri but ed and did no t v ar y s ignifi c antly am ong the 3 g roup s ( P v alue 0 .383). S im ilarl y, mea sur em ent of antr al f ollicl e co unt, as a r efle ct ion of ov ar ian res er ve , did no t d iffer am ong the gr oups ( P valu e 0. 592) . Ind ic at i ons f or tr ea tm ent wer e g ro uped int o non- male r elat ed infert ili ty , m ale rel at ed infer tili ty , a nd oo cy te c ry opr ese rv at ion. Th e l at ter t wo gr oups the ref ore in cluded w om en w ith no prov en inf ert ili ty . Only w om en in th e fi rst tw o g r oups had t he ir o oc yt es f ert iliz ed foll ow ing th e o o cy te p ick up (OPU ). Th ere w ere m or e wo men underg oing OPU fo r oo cy te fre ezing in t he va cc ine gr oup (55.6 % ) c o mp ared t o the o the r group s ( 33.3 % and 7.1 %) : thi s d iffe renc e was cl os e t o st at ist ic al s ignif i canc e ( P valu e 0.0 7). In all g roup s a la rge p rop or ti on of wo men h ad OPU fo r n on-femal e infert ili ty rel at ed indic at ion s ( 50% , r ange 35.7-77. 8 %) . As m ost pat ien ts p ar ti cip at ing i n the st udy we re tre at ed w it h an ant agon ist pr ot oc ol, the us e of h CG only tr igge r w as lim i ted (6.3 % ). The us e of GnR H a goni st tr igg er refle ct ed th e di st ri but ion of OPU fo r oo cy te c ry opre se rv at ion in t he . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted April 13, 2021. ; https://doi.org/10.1101/2021.04.09.21255195doi: medRxiv preprint differ ent g roup s (44% , 44 %, and 28 .6% in t he va c cina ted , C OVID, and c ontr ol g roup s, resp ec ti vely .766 Anti- COVID IgG ant ib odi es : Tabl e 2 des cr ib es th e pr es enc e of a nti-C OVID Ig G indu c ed b y ei the r SA RS-COV-2 infe ct ion or se cond ar y t o va cc ina ti on w ith th e Pfize r - B i oN te ch va cc ine (B NT1 6 2b2 mR All the pati ents wh o re ce iv ed t wo do se s of the BN T162 b2 mR NA va c cine had a high c onc entr at ion of C OVID I gG in th ei r ser um and F F (rang e 850-19,672 and 463-15 ,883 in th e s er um and FF resp ec ti vely ). IgG c onc entr at ion s w ere po si tiv ely c or rel ated w ith th e ti me int erv al fr om th e date of th e v ac c ine: tw o of the pat ie nts t hat ha d onl y r ec ei ved th e fi rs t dose , 13 and 18 da ys befo re OPU, w er e found t o h ar bou r anti- COVID IgG in t he ir se rum and F F ( range 194-228 and 64-198 in t he se rum and F F r es pect iv ely ), whil e the tw o wh o r ec ei ved the fir st do se only 8 d ay s pr i or to OPU had n o me asur abl e anti -COV ID Ig G e it her in t hei r s eru m or FF. All th e pa ti ents w ith po sit iv e ser um anti- COVID IgG had de te ct abl e le ve ls of ant i-COV ID IgG in th ei r foll ic ular fluid. Fig ur e one s how s a line ar as so ci at ion b etw een t he s eru m and FF con cent ra ti ons of an ti- COVID IgG ( R 2 =0.99), sugg es ting a non regul at ed pass age of the ant i- COVID IgG ac r oss th e foll ic ular m e mbr ane . N o diff eren ce wa s f ound b et we en wo men ac qui ring ant i-C OVID an ti b odi es f ollo wing exposu re o r v ac c inat ion, in th e r at i o b et we en FF t o s eru m ant i-COV ID I gG. Ass ess men t of o va ri an folli cle func ti ons: Tabl e 3 des cr ib es t rea tm ent and ou tc om e pa ra me te rs. Th es e pa ra me te rs pr o vid e da ta on the st er oid ogen ic func ti on of th e fol licle ( tr igge r da y ser um and F F e st r adi ol and prog est er one c onc entr at ions ) and t he magni tud e of th e ov a r ec ru itm en t, as refle ct ed by th e numb er of a spi ra ted eggs . Me an s eru m est rad iol on the da y in whi ch the t rigg er inje c ti on w as adm inis ter ed (36 hou rs prio r to OPU ) did no t diff er am ong t he g roup s ( P v alue 0.351 ). Th e n or maliz ed r at io of seru m es tr adi ol on tr igg er d ay / oo cyt e was s im ilar and wi thin th e opti mal range fo r mos t of th e p at ient s in all g roup s. S eru m prog est er one on the s am e da y w as lowe r in t he n on- . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted April 13, 2021. ; https://doi.org/10.1101/2021.04.09.21255195doi: medRxiv preprint expos ed g roup (3 .29, 3 .31 and 1.64 nmol/L in the v ac cin e, COVID and n on-expos ed resp ec ti vely , P val ue .008 ) h ow eve r no diffe renc e was m ea sur ed in s er um pr og est er one on th e d ay of OPU ( 22.6, 26.5 and 1 8.6 nm ol/L in the v ac cine , COVID an d c ontr ol g roup s resp ec ti .40) . Alth ough b oth FF es tr adi ol and p ro gest er one c onc entr at ions w er e hun dreds fold high er co mpa red to s eru m con cen tra ti ons on th e sa me d ay , no diffe ren ce wa s found a mong th e group s ( 2,160, 2,890 and 2,217 nm ol/L f or es tr adi ol and 34,56 9 , 32 .88 6 and 32 ,811 nmol/L fo r pr oge st er one in t he va c cine , COVID and non- expos ed g roup s, r esp ec ti vely , P value s 0 .426 and 0.950 ). The ade qu ac y of th e f olli cula r r esp o nse t o ov ulat ion tr igg ering wa s ass e ssed by s eru m and FF pr oge st er one as well as by th e o oc yt e y ield ( et ri ev ed/t rigg er d ay ma tu re follicl e coun t, o oc yt es re tr iev ed /OP U day se rum pr oge ste r one, ra ti o of mat ur e/ to tal numb er of a spi ra ted o oc yt es ). Oo cy te yi eld w as high in all gr oup s (m ean 152 %, P valu e 0. 772) well a b ov e t he 45 % thr esh old d efining a s ub- opti mal r e spons e. S im ilarl y, th e r at e of m atu r e o o cy tes w as norm al (m ean 0 .72 P Value 0.554 ). The ra ti o be tw een the num be r of a s pira ted o oc yt es and OPU da y pr oge st er one wa s 0.6 3, 0 .4 5, and 0 .61 in t he va cc ine , C OVID, a nd con tr ol gr oups resp ec ti vely , P val ue 0 .372. Ass ess men t of o o cyt e qual it y w it h f olli cular fluid HSPG2 Non e of th es e foll icl e qual ity r epo rt er sur rog at es sugg est ed any me ani ngful differ enc es am ong th e 3 gr oups . The m ean FF HSPG2 fo r all s ample s was 6,340 /ml (m edi an 3,250 , range 302-43,603 ). C omp ar is on of HSPG2 bet we en t he g r oups sh owed si mil ar con cent ra ti ons ( P Valu e 0 .385 ). Discussion: Re cent publ ic at ion s h ave ind ic at ed a po tent ial fo r s ev er e m or bid it y and m ort ali ty am ong partu ri ents affe ct ed by th e e me rgin g va ri ants of the SA RS-C OV-2 vi rus 13 . Despi te th e lo w incid enc e of s ev er e m or bid it y am on g par tur ient s affec ted b y C OVID 19, the CDC add ed . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted April 13, 2021. ; https://doi.org/10.1101/2021.04.09.21255195doi: medRxiv preprint pregnan cy to th e l ist of high- ri sk co nditi ons to pr io ri tize va c cina ti on, a nd AC OG re co mm ends n ot wi thh olding va cc i nati on fr om pr egnant wo men at an y s tag e of th e pregnan cy 14 . The ent hus ias m sur r ounding the v ac cin e r ollo ut wa s a c c omp anied b y unsubs tan tia ted ru m ors spr ead v ia so ci al m edi a, sugg est ing t ha t t he va cc ine ma y le ad to femal e s te ril ity 4 . The r isk f or se ve r e C OVID rela ted illne ss on one hand and t he l ack of knowledg e ab out th e p ot enti al effec ts of an ti-C OVID va cc ina ti on, le d t o muc h app reh ensi on am ong pa ti ents planning to c onc eiv e, res ulting in co uples po stp oning t hei r plans t o con ce iv e 3 13 . To th e b es t of o ur kn o wledge , our st udy is th e fi rst t o d et e rmin e the o var ian invol ve ment w ith th e COVID im mu ne r espon se, a s r efle ct ed b y the pre senc e of an ti-SA RS- COV-2 Ig G in r ec ently va cina ted vs . pa ti ents , all of wh om we re PC R neg at iv e at t he t im e of OPU. Our re sult s sh ow th at all the pa ti ent s r epo rt ed a s C OVID-19 re c ove re es had me asur abl e anti-SA RS-C OV-2 Ig G b ot h in th ei r s eru m and FF. Th e p res enc e of an ti- COVID IgG f ollo wing vac c inat ion wa s s ho wn a s e arl y a s 1 3 day s foll ow ing t he f irs t d os e, b oth in t he se rum and FF. The c onc entr at ion of anti- COVI D IgG c orr ela ted wi th the t im e inte r val fr o m th e va cc ine. The ant i-C OVID Ig G in th e FF r efle ct s i ts se rum c onc entr at ion in a lin ear ass o ci at ion, as prev io usly des cr ib ed f or o the r v er ti cally tr ans mi tte d v iru se s 15 . Our as ses sm ent of a po ten ti al effe ct of eit he r inf ec ti on w ith SA RS-COV- 2 or v ac cin at ion on ova ri an func ti on includ ed s ev er al a spec ts rel at ed to th e eg g-folli cle p er form anc e. Ass ess men t of folli cul ar st er oid oge nesis sh ow ed si mila r and no rm al r a tes of es tr ogen and prog est er one p rod uc ti on. The onl y signifi c ant d iffer enc e w e d et ec ted was a l ow er tr igge r day ser um pr oges te ron e in th e n on-expos ed g roup , a diffe ren ce th at wa s no t sh own on the day of O PU, eit he r in th e s eru m or F F, and th er efor e is unlikel y t o rep re sent a re al b iol ogi c al differ ence . Oth er wis e, n one of the s ynthe ti c p ara m ete rs st udi ed sh ow e d any d iffer enc es am ong th e 3 gr oups . A ss ess men t of the re spons e of t he folli cle s t o the L H/hC G t rigg er sho wed a n or mal and s im ila r r esp o nse in all 3 gr oups. Oo cy te qu alit y ass ess men t: We c omp ared th e c oncen tr ati on of FF HSPG2 , a v alid at ed b i om arke r of oo cy te qu ali ty. FF sampl es sh owed a hig h c onc ent ra ti on of HSPG2 th at wa s no t s ignif ic antly d iffer ent bet we en t he g r oups. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted April 13, 2021. ; https://doi.org/10.1101/2021.04.09.21255195doi: medRxiv preprint Henc e, d esp ite th e cle ar ev iden ce of int im ate foll icul exp osu r e infe ct h SA RS-C OV-2 o r foll ow ing B NT 162b2 mR NA v ac cin e, the s ter o idog enic m ac hine ry of the f olli cle , c ont roll ing t he ulti ma te mat ur ati on of t he o oc yt e and it s h or monal m ili eu, d id not sho w any me asu ra ble d iffer enc e a s co mpa red to non-exp ose d w om en. T his e vid enc e join s o th er d at a on IVF tr ea tm ent o utc om es a mong re c ove re es f ro m C OVID-19 infe c ti on obs er ved in ou r c ent er, wh ic h s ho w ed s im ilar o ut co me s (dat a n ot sh ow n). Strengths and li mitations To th e b es t of o ur kn owl edge th is is the fi rst st udy to ex am ine the pre se nce of na tur al or vac c ine-el ic it ed hu m oral i mmun e r espon se in t he ov ar ian f olli cle. In ad diti on, we als o inve sti gat ed the po ssi ble a sso c ia tion b et w ee n i t s p r es e nc e and sev er al aspe ct s of folli cul ar functi on and o o cyt e yi eld. We ch os e not t o ex am ine the r at e of fer til izat i on and em br yo form at ion and d ev elop ment , a s t he y inv olv e the m ale g am et es and ma y int r oduc e differ ence s un rela ted t o the st udy q uest i on. Thi s i s h ow ev er a sm all st udy, c o m pris ing a m ixed f ert ile and infer til e populat i on, and i ts con clus ions sh ould be supp or ted an d val ida ted by larg er st udi es. Due t o it s t im ing, ou r study w as abl e t o as ses s s ho rt te rm affec ts of v a cc ine and di se ase b ut ca nnot r ule ou t la te r seq uela e. Conclusions Expos ure t o ei the r t he SA RS-COV-2 vir us or th e B NT 162b2 m RN A va cc i ne r esult s in a rap id form at ion of anti- COVID IgG th at c a n be d et ec ted in th e foll icul ar flu id, co rr elat ing w it h seru m c oncen tr at ions . In ou r s tudy , nei the r inf ec ti on o r the B NT162 b2 mR NA va c cine , no r the im mun e r esp onse t o t he m, re sul ted in an y m ea sur abl e d etr im ent al effec t on th e functi on of t he ov ar ian f olli cle. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted April 2021. ; https://doi.org/10.1101/2021.04.09.21255195doi: Overvi ew. CDC .gov: Centers for Diseas e Control & Prevention ; 3/31/2021 2021. 2. Abu Jaba l K, Ben-Amram H, B eiru ti K, et al. Impact of age , ethnici ty, sex an d prior infection status on immunogenici ty following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world Isra el, Decembe r 2020 to Jan uary 2 021. Euro Surveill. 2021;26(6). 3. Flynn AC, Kavanagh K, Smith AD, Poston L, White SL. The Imp act of the COVID-19 Pandemic on Pregnancy Planning Behaviors. W ome ns Healt h Rep (New Roc helle). 2021;2(1):71-77. 4. COVID-19 vaccine and infertility: basel es s claims and unfounded social media pan ic [press releas e]. Fer tility 2021. L, Hao-Ran W, et al . Pot ential influenc e of COVID-19/ACE2 on th e female reprod uctive system. M ol Hum Re pro d. 2 020;26(6):367-373. 6. Chen CP, Chen LF, Yang SR, et al. Functio nal charact eriza tion of th e human placen fusogenic membrane pr ot ein syncytin 2008;79(5):815-823. 7. D, involvement of HERV-W Env glycoprotein in human tropho blast cell atio n. Mol Cell Biol ss release]. ristics receiving eith er G nRH agonist o r hCG for ovulation induction. Hu m R epr o d. 2006;21(8):2126-2130. 10. Vaughan DA, Harri ES, Mocanu EV. Serum estr adiol: reprod uctive outc ome: an an alysis of dat a from >9000 IVF cycles in the Republic o f Ireland. J Assist Reprod Gen et . 2016;33(4):481-488 . 11. Popovic-Todorovic B, Santos-Ribeir o S, Drakopoulos P, et al. Predict ing suboptima l oocyte yield GnRH agonist t rigger by measu ring serum LH Hum Reprod . 2019;34(10):2027-2035. 12. Bayasula, Iwase Kobayashi H, e t al. A p rote omic analysis of human follicular fluid: comparison betwee oocyt es and non-ferti l ized oocytes in th e same pa tien t. J Assist Reprod Gen et . 2013;30(9):1231-1238. 13. Zambrano LD, Ellington eristics of Symptoma tic with Labo rato ry-Confirmed SARS-CoV-2 Infection by Pregnancy Status - United S tat es, Ja nuary 22-Octob er 3, 202 0. MMWR M orb Mor Wkl y Rep. 2020; 69(44):1641- 1647. 14. ACOG Exp ert W ork Gr oup in collabo rati o n with Laura E. Riley MRB, MD; Denise J. Jamieson, MD, MPH; Brenna L. Hugh es, MD, MSc; G ee Linda O'Neal Ecker t, MD; Mark Turrenti ne, MD; an d roll, MPH. Vaccinating Pregnant and Lact ating Pati e nts Against G. Obe stet G; 2020. 15. Ardizzoni A, Manca L, Capoda nno F, e t al. Detection of follicular fluid and se rum a ntibodies by prote in microarr ays in women undergoin g in vitro fertiliza tion t rea tmen t. unol . 2011;89(1):62-69. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted April 13, 2021. ; https://doi.org/10.1101/2021.04.09.21255195doi: medRxiv preprint Figur e 1: The r elat i onship of f olli cu lar flu id ant 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted April 13, 2021. ; Table 1: Patient's demograp hics by stud y group Vaccine Disease Non ex posed Total Number 9 9 14 32 P Value Age Mean \u00b1 *STDEV 35.3 0.383 Median 35 34 33 Antra l follicular count Mean \u00b1 STDEV 13.3 15.6 \u00b1 6.7 14.4 \u00b1 5.7 0.592 Median 14 13 17.5 14.5 Indicatio n Male (%) 2 (22.2%) 1 (11.1%) 4 (28.6%) 7 (21.9%) 0.113 Non male 2 (22.2%) 5 (55.6%) 9 (64.3%) 16 (50% ) Egg Freezing (%) 5 (55.6%) 3 (33.3%) 1 (7.1%) 9 (28.1%) Total non-Infertil (44.4%) pres ence Vaccine Disease Non ex posed Total Number 9 9 14 32 P Value Serum Positive 7 8 0 15 <0.001 Negative 2 1 14 17 Positive 46.7% 88.9% 0 FF** Positive 7 8 0 15 <0.001 Negative 2 1 14 17 Positive 46.7% 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted April 13, 2021. ; https://doi.org/10.1101/2021.04.09.21255195doi: medRxiv preprint Table 3: Treatment pa rameters by study group Paramete r Group Vaccine Disease Non ex posed Total Number 9 9 14 32 P Value Trigger 0.67 2.6 \u00b1 1.54 0.008 Median 2.63 3.26 1.35 2.46 Type of trigger hCG only (%) 1 (11.1%) 0 1 (7.1%) 2 11.2 \u00b1 6.7 11.5 \u00b1 6.7 0.877 Median 8 10 10 9 Matur e oocytes Mean (STDEV) 7.25 \u00b1 2.77 7.75 \u00b1 4.7 7.8 \u00b1 4.1 0.870 Median 6.5 7 6.5 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted "}